
Morepen gets regulatory clearance for fatty liver drug development
Morepen Laboratories gains CDSCO approval for Resmetirom bioequivalence studies, positioning the company for global NASH treatment market growth. Morepen Laboratories has received approval from India’s Central Drugs Standard Control Organization (CDSCO) to conduct bioequivalence studies for Resmetirom tablets, a potential treatment for non-alcoholic steatohepatitis (NASH), the company announced today. The shares of Morepen Laboratories Limited...
Read more